Background--CD4+ T helper (Th) cells, including Th1, Th2, and Th17 cells, play critical roles in angiotensin II-induced hypertension. Th22 cells, a novel subset of Th cells, take part in cardiovascular diseases by producing . This study aimed to investigate whether IL-22 is involved in hypertension.
H ypertension is a common clinical disorder characterized by increased systolic blood pressure (SBP) and/or diastolic blood pressure (BP). 1 Hypertension is a major modifiable risk factor for cardiovascular disease and leads to serious cardio-cerebrovascular complications, including heart failure, acute myocardial infarction, and stroke, which account for %30% of all deaths worldwide. 2, 3 CD4+ T helper (Th) cells are critical in the angiotensin II-induced hypertension model. Th cells can be functionally subdivided into 3 types according to their cytokine secretion profiles: Th1, Th2, and Th17 cells, which mainly secrete IFN-c (interferon c), IL-4, and IL-17, respectively. Both IFN-c and IL-17 deficiency significantly reduce elevated BP in angiotensin IIinduced hypertension models. 4 ,5 IL-4 deficiency significantly accelerates cardiac fibrotic remodeling in angiotensin IIinduced hypertrophy, although it has no effect on BP.
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Th22 cells, the fourth subpopulation of Th cells, were recently identified in 2009. [7] [8] [9] Data from clinical and experimental investigations have demonstrated that Th22 cells take part in inflammatory and autoimmune diseases such as atherosclerosis, 10 myocarditis, 11, 12 rheumatoid arthritis, 13 and systemic lupus erythematosus 14 by secreting IL-22, which is a proinflammatory cytokine that belongs to the IL-10 cytokine family. The IL-10 cytokine family comprises 6 members, including IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26. 15 IL-10 is an anti-inflammatory cytokine, and its antihypertensive role has been identified in numerous studies. [16] [17] [18] unknown. IL-24 is secreted by both immune and nonimmune cells. Lee et al found that the expression of IL-24 decreased in spontaneously hypertensive rats but increased after treatment with antihypertensive drugs. 22 In addition, IL-24 treatment attenuated the expression of vascular inflammation and hypertension-related genes in mouse vascular smooth muscle cells, indicating that IL-24 is a novel therapeutic target for hypertension. IL-26 is a proinflammatory cytokine that is mainly secreted by Th17 cells. Corvaisier et al found that IL-26 induces proinflammatory cytokine secretion and upregulates Th17 cell generation. 23 These results suggest that IL-26 may play a pathogenic role in hypertension by upregulating Th17-type responses and promoting the production of proinflammatory cytokines. IL-22 is secreted by  numerous types of cells including activated Th1 cells, Th17  cells, Th22 cells, natural killer cells, natural killer T cells and  lymphoid tissue-inducer cells, and Th22 cells are the critical  source of IL-22 during the later stages of inflammation. 24, 25 IL-22 is upregulated in many chronic inflammatory and autoimmune diseases, and the exact role of IL-22 appears to depend on specific inflammatory microenvironments: A protective role of IL-22 was found in a myocarditis model, 11, 12 whereas a pathogenic role of IL-22 has been demonstrated in atherosclerosis. 10 Whether IL-22 plays a role in hypertension remains unknown. This study aimed to investigate the effect of IL-22 on angiotensin II-induced hypertension.
Materials and Methods

Animals and Animal Model
Male C57BL/6J mice (26. 
BP Measurement
The SBP and the heart rate of the mice were detected via a carotid catheter-calibrated tail-cuff system (CODA, Kent Scientific) before and after the mice were treated, as described previously.
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Quantitative Polymerase Chain Reaction
The total mRNA was extracted with TRIZOL Reagent W, and cDNA was synthesized from 2 mg total mRNA using oligo(dT) primers and a reverse transcription kit according to the manufacturer's instructions. Polymerase chain reaction amplifications were performed using LightCycler 480 SYBR Green Master Mix (Roche Diagnostics). The relative mRNA expression levels of IL-1b, IL-6, IL-17, TNF-a, IFN-c, ICAM, and MCP-1 were investigated, the results were normalized against the expression levels of GAPDH (glyceraldehyde-3-phosphate dehydrogenase). The reverse transcription quantitative polymerase chain reaction primer sequences are shown in Table 1 .
Vascular Ring Experiments
To measure vascular reactivity, parts of the aorta were placed in cold physiological salt solution. 31 The aortic rings were cut into 3 to 4 mm sections and were connected to an isometric force transducer in a custom-designed 15-mL organ chamber filled with 37°C cold physiological salt solution and bubbled with 95% O 2 and 5% CO 2 . Parts of the vascular rings were treated with indomethacin (10 lmol/L, 60 minutes). Concentration-force curves were obtained in a half-log, cumulative fashion to acetylcholine and sodium nitroprusside following contraction to an EC70 concentration (1 mmol/L) of phenylephrine.
Western Blot Analysis
The total protein of the thoracic aorta was extracted and detected with the BCA Protein Assay Kit (Thermo Fisher Scientific). Approximately 20 lg total protein was separated by electrophoresis on 8% Laemmli sodium dodecyl sulfate polyacrylamide gels, and after electrophoresis, they were transferred to Immobilon-FL PVDF membranes (Millipore). The membranes were blocked with 5% nonfat milk, and the membranes were then incubated with anti-STAT3, antiphosphorylated STAT3, anti-eNOS (anti-endothelial nitric oxide), anti-phosphorylated eNOS threonine 495 (Thr495), and anti-GAPDH antibodies at 4°C overnight, followed by incubation with the secondary antibody at room temperature for 1 hour. The blots were scanned using a 2-color infrared imaging system (Odyssey; LI-COR Biosciences).
Collection of Human Blood Samples
Fasting venous peripheral blood samples from healthy persons (n=24) and newly diagnosed hypertensive patients (n=46) were collected at the People's Hospital of Guangxi Table 2 , which shows unadjusted analyses.
Statistical Analyses
The SPSS version 18.0 (IBM Corp) was used for data analysis. Data from animal experiments are expressed as meanAESD. Differences between 2 groups were compared by Student t tests. Differences between multiple groups were compared by 1-way ANOVA, followed by Tukey's multiple comparisons test. For the human experiments, data with a normal distribution were expressed as meanAESD. Differences between 2 groups were compared by Student t tests, whereas data with abnormal distribution were expressed as lower quartile and upper quartile and were compared by the Mann-Whitney U test; categorical variables are presented as counts (percentages). The Spearman correlation was used to calculate correlations between SBP, diastolic BP, and serum IL-22 levels. Multiple regression tests were used to analyze the associations between serum IL-22 and risk factors for hypertension in human subjects. P<0.05 was considered significant and was the threshold used to reject the null hypothesis.
Results
Chronic Angiotensin II Infusion Increased Th22/ IL-22 Levels in Mice
Compared with baseline levels, the percentage of Th22 cells significantly increased by week 1, continued to increase by week 2, reached a peak, and then was continuously maintained at high levels through the end of 4 week ( Figure 1A and 1B) . Similar results were obtained for serum IL-22 levels ( Figure 1C ).
IL-22 Increased Angiotensin II-Induced Hypertension
At baseline, no differences were observed in SBP among the 5 groups (Figure 2A) . Results similar to the changes in the percentage of Th22 cells and serum IL-22 were found for SBP with chronic angiotensin II infusion, and treatment with rIL-22 increased angiotensin II-induced hypertension (week 4 SBP: angiotensin II and rIL-22 group: 179AE7 mm Hg; angiotensin II group: 155AE4 mm Hg; Figure 2A ). Mouse anti-IL-22 monoclonal antibody (mAb)partly prevented BP elevation (week 4 SBP: angiotensin II and anti-IL-22 mAb group: 132AE4 mm Hg; angiotensin II group: 155AE4 mm Hg; Figure 2A) . No difference in SBP was found between the angiotensin II group and the angiotensin II with IgG group. In addition, there were no significant differences in heart rate among the 5 groups ( Figure 2B ).
IL-22 Aggravated Both Systemic and Local Inflammation
To examine the effect of IL-22 on systemic inflammation, we tested the circulatory cytokine levels of the 5 groups. Compared with the angiotensin II group, the angiotensin II and rIL-22 group had higher levels of IL-1b, IL-6, IL-17A, TNF-a, IFN-c, ICAM, and MCP-1 ( Figure 3A) . Opposite results were found for the angiotensin II and anti-IL-22 mAb group compared with the angiotensin II group ( Figure 3A) , and no significant difference was found for the angiotensin II and IgG group. In addition, we analyzed the mRNA expression of these cytokines in the aortas of the mice. Compared with the angiotensin II group, higher mRNA levels of IL-1b, IL-6, IL-17A, TNF-a, IFN-c, ICAM, and MCP-1 were found in the angiotensin II and rIL-22 group (Figure 3B ), lower mRNA levels of these cytokines were found in the angiotensin II and anti-IL-22 mAb group ( Figure 3B ), and isotype IgG had no effect on mRNA expression.
IL-22 Aggravated Angiotensin II-Induced Vascular Dysfunction
We next tested the endothelium-dependent and -independent relaxation responses of endothelium-intact aortas isolated from mice that had been treated for 4 weeks. Angiotensin II significantly reduced acetylcholine-induced relaxation responses, increased phenylephrine-induced contractions, and mildly decreased sodium nitroprusside-induced relaxation responses ( Figure 4A through 4D) , as reported previously; therefore, angiotensin II-induced hypertension was associated with endothelial dysfunction. The effect of angiotensin II on endothelial dysfunction was aggravated by rIL-22, prevented by anti-IL-22 mAb, and was not affected by isotype IgG (Figure 4A through 4C) . To investigate the effect of the inflammatory response on endothelial function, parts of the vascular rings were treated with indomethacin, revealing that indomethacin prevented the effect of IL-22 on angiotensin II-induced vascular dysfunction ( Figure 4D ).
The STAT3 Pathway Mediated the Effect of IL-22
STAT3 and eNOS Thr495 phosphorylation was measured by Western blot in mouse aortas, and the results demonstrated that angiotensin II significantly increased phosphorylation of the STAT3 pathway and eNOS Thr495. This effect could be further increased by rIL-22 and partly prevented by anti-IL-22 mAb, and no significant difference was observed for treatment with isotype IgG (Figure 5A and 5B).
To determine whether the STAT3 pathway plays a critical role in the effect of IL-22 on BP and endothelial function, the special STAT3 pathway inhibitor S31-201 was used in rIL-22-treated mice. Treatment with S31-201 prevented the IL-22-induced increase in angiotensin II-induced hypertension (week 4 SBP: angiotensin II, rIL-22, and S31-201 group: 110AE3 mm Hg; angiotensin II and rIL-22 group: 179AE4 mm Hg; angiotensin II and S31-201 group 111AE4 mm Hg; Figure 6A ). S31-201-treated mice also exhibited decreased STAT3 phosphorylation ( Figure 6B ). In addition, the effect of IL-22 on angiotensin II-induced vascular dysfunction was prevented by S31-201 ( Figure 6C through 6E) .
Serum IL-22 Levels Increased in Hypertensive Patients
Serum IL-22 levels were significantly increased in hypertensive patients compared with control participants (Figure 7A ). Correlation analysis revealed that the level of IL-22 was positively correlated with SBP and diastolic BP in the hypertensive patients ( Figure 7B and 7C) . Furthermore, multivariate analysis taking into account the major risk factors for hypertension revealed higher levels of IL-22 in participants who smoked, whereas other risk factors, including male sex, older age, obesity, smoking, drinking, and family history had no significant effect on serum IL-22 levels. The serum levels of each group are listed in Table 3 (adjusted model).
Discussion
Previous studies have revealed that angiotensin II not only promotes T-cell proliferation but also regulates Th1, Th2 and Th17 cell activities in vivo, thereby playing vital roles in angiotensin II-induced hypertension and target organ damage. Shao et al found that exogenous angiotensin II directly promoted the production of IFN-c and inhibited the production of IL-4 in cultured rat T lymphocytes, which is associated with the onset of kidney injury. 32 Moreover, using a mouse atherosclerosis model, Mazzolai et al reported that endogenous angiotensin II elicited a Th1 response, which is widely identified as a type of T lymphocyte with a proatherosclerotic role, and led to unstable atherosclerotic plaques. 33 Taken together, these studies demonstrated that the imbalance promoted IL-17 production in cultured mouse T lymphocytes but had no effect on IL-17 production in cultured human T lymphocytes. 4, 35 In the present study, we investigated the role of Th22/ IL-22 in an angiotensin II-induced hypertension model. We first measured the levels of Th22/IL-22 in angiotensin II-infused mice and controls. The results showed that 2 weeks of angiotensin II treatment significantly increased Th22 cells and IL-22 levels compared with controls, and these effects were maintained until the end of the experiment. In fact, the changes in Th22 cells and IL-22 levels were consistent with the BP values of the angiotensin II-treated mice. Consequently, these results revealed that Th22/IL-22 responses are upregulated by angiotensin II in hypertension.
To determine whether IL-22 plays a role in the effect of angiotensin II on BP regulation, we used rIL-22 to enhance or anti-IL-22 mAb to block the effects of IL-22 in angiotensin II-treated mice. The resulted showed that rIL-22 treatment further increased BP up to 179 mm Hg, whereas anti-IL-22 mAb induced a sharp decrease in BP to as low as 132 mm Hg, although this value was still higher than that of the control group. These findings suggest a direct effect of IL-22 on BP regulation in angiotensin II-induced hypertensive mice.
Inflammation plays a critical role in hypertension. Many inflammatory mediators, including IFN-c, IL-17, IL-1b, IL-6, TNF-a, and chemokine MCP-1, significantly promote the development of hypertension and target organ damage in hypertension models. 4, 5, [35] [36] [37] [38] [39] [40] Accumulating evidence has demonstrated that IL-22 increases the expression of IL-1b, IL-6, IL-17, and MCP-1, suggesting that IL-22 might be involved in BP regulation by inducing the production of these inflammatory mediators. Therefore, we measured whether local and systemic inflammatory responses were regulated by IL-22. We found that rIL-22 increased the production of these inflammatory mediators in the angiotensin II-induced hypertension model, whereas anti-IL-22 mAb significantly decreased the levels of inflammatory mediators. Taken together, these results suggest that IL-22 may be involved in hypertension by amplifying the inflammatory response. Accumulating evidence has demonstrated that endothelial dysfunction promotes BP elevation and serves as a bridge between angiotensin II and hypertension. 18, [41] [42] [43] In the present study, we investigated whether IL-22 plays a role in regulating endothelial function. The results showed that rIL-22 further promoted the effect of angiotensin II on endotheliumdependent and -independent relaxation responses, whereas anti-IL-22 mAb reversed the effect of angiotensin II. Moreover, eNOS Thr495 phosphorylation is crucial for eNOS activity and nitric oxide release, thereby playing a role in endothelial function and BP homeostasis. 44, 45 Consequently, the activity of eNOS Thr495 phosphorylation is important for endothelial function. In the present study, we found that rIL-22 significantly upregulated eNOS Thr495 phosphorylation, whereas anti-IL-22 mAb significantly downregulated eNOS Thr495 phosphorylation; therefore, IL-22 might elevate BP by impairing endothelial function. It is well known that excessive activation of the STAT3 pathway is critical in angiotensin II-induced inflammatory responses and oxidative stress, which result in hypertension. 27, 46 Evidence from animal experimental studies has shown that after binding to the heterodimeric receptor complex IL-10R b chain and IL-22R, IL-22 activates the JAK/STAT pathway predominantly via STAT3. 12, 47, 48 Consequently, we investigated whether the STAT3 pathway mediated the effect of IL-22 on hypertension. First, we found that STAT3 phosphorylation is upregulated by rIL-22 and inhibited by anti-IL-22 mAb, indicating that the activity of STAT3 is associated with IL-22 levels. Second, to determine whether STAT3 plays a critical role in the effects of IL-22 on BP and endothelial function, mice were treated with the STAT3 inhibitor S3I-201, which selectively inhibits STAT3 phosphorylation, dimerization, and STAT3-dependent gene transcription. The results showed that S3I-201 treatment significantly inhibited STAT3 phosphorylation and led to a reduction in BP. Taken together, STAT3 mediates the effects of IL-22 on endothelial function and hypertension. To extend our results to human hypertension, we examined the serum levels of IL-22 in normotensive and newly diagnosed hypertensive patients. The serum levels of IL-22 were significantly higher in hypertensive patients than in normotensive participants. In hypertensive patients, the serum levels of IL-22 were positively correlated with SBP and diastolic BP. These results suggest a tight relationship between IL-22 and human hypertension; however, the sample used was too small, and other types of hypertension, such as white-coat syndrome, poorly controlled hypertension, and well-controlled hypertension, were not considered.
In summary, the results of our study are the first to demonstrate that the Th22/IL-22 response is upregulated by angiotensin II treatment and that IL-22 promotes BP elevation in angiotensin II-induced hypertension. Although the exact mechanisms of IL-22 on hypertension have not been fully clarified, amplifying inflammatory response and inducing endothelial dysfunction may mediate the effect of IL-22 on hypertension. Consequently, blocking the effects of Th22/ IL-22 could be a therapeutic option for preventing and treating hypertension.
Conclusions
This study revealed that binding of IL-22, IL-22R1, and IL-10R2 could further activate the STAT3 pathway and aggravate angiotensin II-induced endothelial dysfunction and hypertension, whereas neutralization of IL-22 had an opposite biological function. IL-22 is a new target for hypertension.
